DK2438083T3 - Serum-amyloid-P-derivater og disses fremstilling og anvendelse - Google Patents
Serum-amyloid-P-derivater og disses fremstilling og anvendelse Download PDFInfo
- Publication number
- DK2438083T3 DK2438083T3 DK10784210.6T DK10784210T DK2438083T3 DK 2438083 T3 DK2438083 T3 DK 2438083T3 DK 10784210 T DK10784210 T DK 10784210T DK 2438083 T3 DK2438083 T3 DK 2438083T3
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptide
- sap polypeptide
- sap
- linked
- oligosaccharide chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Claims (38)
1. Glycosyleret humant serum-amyloid-P (SAP)-polypeptid omfattende en N-forbundet oligosaccharidkæde, hvor i det mindste én gren af oligosaccharidkæden afsluttes med en a2,3-forbundet sialinsyregruppe.
2. Glycosyleret humant SAP-polypeptid ifølge krav 1, hvor polypeptidet omfatter en aminosyresekvens, som er i det mindste 85% identisk med aminosyresekvensen ifølge SEQ ID NO: 1.
3. Glycosyleret humant SAP-polypeptid ifølge krav 1 eller 2, hvor den N-forbundne oligosaccharidkæde omfatter en pentasaccharidkerne af Man[(a1,6-)-(Man(a1,3)]-Man(81,4)-GlcNAc(81,4)-GlcNAc(81 ,N)-Asn.
4. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1-3, hvor oligosaccharidkæden omfatter i det mindste én gren, som har strukturen NeuNAc2a3Gal84GlcNAc82Mana6.
5. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1-4, hvor SAP polypeptidet er et rekombinant polypeptid.
6. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1-5, hvor polypeptidet omfatter en aminosyresekvens, som er i det mindste 90% identisk med aminosyresekvensen ifølge SEQ ID NO: 1.
7. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1-5, hvor polypeptidet omfatter en aminosyresekvens, som er i det mindste 95% identisk med aminosyresekvensen ifølge SEQ ID NO: 1.
8. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1-5, hvor polypeptidet omfatter en aminosyresekvens, som er i det mindste 96% identisk med aminosyresekvensen ifølge SEQ ID NO: 1.
9. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1-5, hvor polypeptidet omfatter en aminosyresekvens, som er i det mindste 99% identisk med aminosyresekvensen ifølge SEQ ID NO: 1.
10. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1-5, hvor polypeptidet omfatter en aminosyresekvens, som er i det mindste 99% identisk med aminosyre-sekvensen ifølge SEQ ID NO: 1.
11. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1-5, hvor polypeptidet omfatter aminosyresekvensen ifølge SEQ ID NO: 1.
12. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1-11, hvor polypeptidet er et fusionsprotein, som omfatter et SAP-domæne og ét eller flere heterologe domæner.
13. Glycosyleret humant SAP-polypeptid ifølge krav 12, hvor det ene eller flere heterologe domæner fremmer én eller flere af in vivo stabilitet, in vivo halveringstid, optagelse/indgivelse, vævslokalisering eller distribution, dannelse af proteinkomplekser og/eller oprensning.
14. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1-13, hvor polypeptidet omfatter én eller flere aminosyrerester.
15. Glycosyleret humant SAP-polypeptid ifølge krav 14, hvor den ene eller flere modificerede aminosyrerester omfatter en PEGyleret aminosyre, en prenyleret aminosyre, en acetyleret aminosyre, en biotinyleret aminosyre, og/eller en aminosyre konjugeret til et organisk derivatiseringsmiddel.
16. Glycosyleret humant SAP-polypeptid ifølge krav 15, hvor den ene eller flere modificerede aminosyrerester fremmer én eller flere af in vivo stabilitet, in vivo halveringstid, optagelse/indgivelse, vævslokalisering eller distribution, dannelse af proteinkomplekser og/eller oprensning.
17. Farmaceutisk fremstilling, som er egnet til anvendelse i et pattedyr, omfattende det humane SAP-polypeptid ifølge ethvert af kravene 1 til 16, og et farmaceutisk acceptabelt bærestof.
18. Fremgangsmåde til fremstilling af et humant SAP-polypeptid omfattende en N-forbundet oligosaccharidkæde, hvor i det mindste én gren af oligosaccharidkæden afsluttes med en a2,3-forbundet sialinsyregruppe, hvilken fremgangsmåde omfatter: i) ekspression af et humant SAP-polypeptid i en celle; og ii) isolering af det humane SAP-polypeptid fra cellen.
19. Fremgangsmåde ifølge krav 18, hvor cellen er en CHO-celle.
20. Fremgangsmåde ifølge krav 18 eller 19, hvor SAP-polypeptidet er et polypeptid ifølge ethvert af kravene 1 til 16.
21. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1 til 5, 7 eller 12 til 16 eller fremgangsmåden ifølge ethvert af kravene 18-20, hvor alle grene i oligosaccharidkæden afsluttes med a2,3-forbundne sialinsyregrupper.
22. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1 til 5, 7 eller 12 til 16 eller fremgangsmåden ifølge ethvert af kravene 18-20, hvor oligosaccharidkæden er i det væsentlige fri for a2,6-forbundne sialinsyregrupper.
23. Fremgangsmåde ifølge krav 18, som yderligere omfatter enzymatisk eller kemisk ændring af det isolerede SAP-polypeptid for tilvejebringelse af et SAP-polypeptid, som har en modificeret oligosaccharidkæde.
24. Fremgangsmåde ifølge krav 23, hvor processen med enzymatisk eller kemisk ændring af det isolerede SAP-polypeptid fjerner én eller flere afsluttende a2,6-forbundne sialinsyregrupper fra oligosaccharidkæden.
25. Fremgangsmåde ifølge krav 24, hvor processen med enzymatisk eller kemisk at ændre det isolerede SAP-polypeptid erstatter én eller flere afsluttende a2,6-forbundne sialinsyregrupper på oligosaccharidkæden med én eller flere a2,3-forbundne sialinsyregrupper.
26. Glycosyleret humant SAP-polypeptid ifølge ethvert af kravene 1 til 16 eller fremgangsmåden ifølge ethvert af kravene 18 til 25, hvor det isolerede SAP-polypeptid har en IC50 for inhibering af differentieringen af monocytter til fibrocytter in vitro, som er mindre end halvdelen af denne for en tilsvarende prøve af vildtype SAP isoleret fra humant serum.
27. Fremgangsmåde til fremstilling af et humant SAP-polypeptid, omfattende: i) tilvejebringelse af et glycosyleret humant SAP-polypeptid, hvor det glycosy-lerede humane SAP-polypeptid omfatter en N-forbundet oligosaccharidkæde; og ii) enzymatisk eller kemisk ændring af den N-bundne oligosaccharidkæde af det humane SAP-polypeptid, for tilvejebringelse af et modificeret glycosyleret humant SAP-polypeptid, hvor i det mindste én gren af oligosaccharidkæden afsluttes med en a2,3-forbundet sialinsyregruppe.
28. Fremgangsmåde ifølge krav 27, hvor processen med enzymatisk eller kemisk at ændre den N-forbundne oligosaccharidkæde i SAP-polypeptidet fjerner én eller flere afsluttende a2,6-forbundne sialinsyregrupper fra oligosaccharidkæden.
29. Fremgangsmåde ifølge krav 27, hvor processen med enzymatisk eller kemisk at ændre den N-forbundne oligosaccharidkæde i det humane SAP-polypeptid erstatter én eller flere afsluttende a2,6-forbundne sialinsyregrupper på oligosaccharidkæden med én eller flere a2,3-forbundne sialinsyregrupper.
30. Fremgangsmåde ifølge ethvert af kravene 27-29, hvor den N-forbundne oligosaccharidkæde har i det mindste 50% færre a2,6-forbundne sialinsyregrupper end et vildtype humant SAP protein isoleret fra humant serum.
31. Fremgangsmåde ifølge ethvert af kravene 27-29, hvor den N-forbundne oligosaccharidkæde er i det væsentlige fri for a2,6-forbundne sialinsyregrupper.
32. Fremgangsmåde ifølge ethvert af kravene 27-31, hvor alle grene i oligosaccharidkæden afsluttes i a2,3-forbundne sialinsyregrupper.
33. Fremgangsmåde ifølge ethvert af kravene 27-32, hvor det modificerede glycolyserede SAP-polypeptid har en IC50 til at inhibere differentieringen af monocytter til fibrocytter in vitro, som er mindre end halvdelen af denne for en tilsvarende prøve vildtype SAP isoleret fra humant serum.
34. Fremgangsmåde til fremstilling af et humant SAP-polypeptid, omfattende: i) tilvejebringelse af et humant SAP-polypeptid, og ii) enzymatisk eller kemisk ændring af det humane SAP-polypeptid for tilvejebringelse af et glycosyleret humant SAP-polykpeptid, som omfatter et N-forbundet oligosaccharid, hvor i det mindste én gren af oligosaccharidkæden afsluttes med en a2,3-forbundet sialinsyregruppe.
35. Humant SAP-polypeptid omfattende en N-forbundet oligosaccharidkæde, hvor i det mindste én gren af oligosaccharidkæden afsluttes med en a2,3-forbundet sialinsyregruppe, fremstillet ved en proces, som omfatter: i) ekspression af et SAP-polypeptid i en CHO-celle; og ii) isolering af SAP-polypeptidet fra cellen.
36. Humant SAP-polypeptid ifølge krav 35, hvor SAP-polypeptidet har en IC50 til at inhibere differentieringen af monocytter til fibrocytter in vitro, som er mindre end halvdelen af denne for en tilsvarende prøve af vildtype SAP isoleret fra humant serum.
37. CHO-celle, som omfatter et humant SAP-polypeptid omfattende en N-forbundet oligosaccharidkæde, hvor i det mindste én gren af oligosaccharidkæden afsluttes med en a2,3-forbundet sialinsyregruppe.
38. SAP-polypeptid ifølge ethvert af kravene 1-16 til anvendelse ved behandling eller forhindring af en tilstand eller lidelse valgt fra en inflammatorisk lidelse, en fibrotisk eller fibroproliferativ lidelse, en hypersensitivitetslidelse, en autoimmun lidelse eller mucositis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21793109P | 2009-06-04 | 2009-06-04 | |
| PCT/US2010/037542 WO2010141918A1 (en) | 2009-06-04 | 2010-06-04 | Serum amyloid p derivatives and their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2438083T3 true DK2438083T3 (da) | 2016-03-07 |
Family
ID=43298203
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10784210.6T DK2438083T3 (da) | 2009-06-04 | 2010-06-04 | Serum-amyloid-P-derivater og disses fremstilling og anvendelse |
| DK15197076.1T DK3042915T3 (da) | 2009-06-04 | 2010-06-04 | Serum-amyloid-P-derivater og disses fremstilling og anvendelse |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15197076.1T DK3042915T3 (da) | 2009-06-04 | 2010-06-04 | Serum-amyloid-P-derivater og disses fremstilling og anvendelse |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9296800B2 (da) |
| EP (2) | EP2438083B1 (da) |
| JP (3) | JP5801293B2 (da) |
| CN (1) | CN102574902B (da) |
| AU (1) | AU2010256426B2 (da) |
| BR (2) | BR122020010980B1 (da) |
| CA (1) | CA2764461C (da) |
| CO (1) | CO6480917A2 (da) |
| CR (1) | CR20110640A (da) |
| CY (1) | CY1120817T1 (da) |
| DK (2) | DK2438083T3 (da) |
| EA (1) | EA030332B1 (da) |
| ES (2) | ES2692815T3 (da) |
| HK (1) | HK1168603A1 (da) |
| HR (2) | HRP20160221T1 (da) |
| HU (1) | HUE026737T2 (da) |
| IL (1) | IL216744A (da) |
| LT (1) | LT3042915T (da) |
| MX (1) | MX2011012738A (da) |
| MY (1) | MY158761A (da) |
| NZ (1) | NZ596849A (da) |
| PL (2) | PL2438083T3 (da) |
| PT (1) | PT3042915T (da) |
| SI (2) | SI3042915T1 (da) |
| TR (1) | TR201815592T4 (da) |
| UA (1) | UA110323C2 (da) |
| WO (1) | WO2010141918A1 (da) |
| ZA (1) | ZA201108857B (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8247370B2 (en) * | 2006-12-04 | 2012-08-21 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| US20090092574A1 (en) | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
| US9884899B2 (en) * | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| US8497243B2 (en) * | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| CA2755047C (en) | 2009-03-11 | 2018-12-04 | Promedior, Inc. | Treatment methods for autoimmune disorders |
| JP5797565B2 (ja) * | 2009-03-11 | 2015-10-21 | プロメディオール， インコーポレイテッド | 過敏性障害（ｈｙｐｅｒｓｅｎｓｉｔｉｖｅ ｄｉｓｏｒｄｅｒ）に対する処置および診断方法 |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| ES2552793T3 (es) | 2009-06-17 | 2015-12-02 | Promedior Inc. | Variantes de SAP y su uso |
| FR2969153B1 (fr) * | 2010-12-17 | 2014-10-17 | Lab Francais Du Fractionnement | Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee |
| WO2012158672A2 (en) | 2011-05-16 | 2012-11-22 | Polymedix, Inc. | Compounds for use in treatment of mucositis |
| JP6340319B2 (ja) * | 2011-12-21 | 2018-06-06 | プロメディオール， インコーポレイテッド | 血清アミロイドｐ−抗体融合タンパク質 |
| EP3718558A1 (en) * | 2013-10-08 | 2020-10-07 | Promedior, Inc. | Methods for treating fibrotic cancers |
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| CN105372214B (zh) * | 2014-08-18 | 2019-06-28 | 中国科学院上海有机化学研究所 | 一种鉴定新红细胞生成刺激蛋白的n-连接寡糖结构的方法 |
| MX2019002734A (es) * | 2016-09-13 | 2019-05-27 | Bayer Healthcare Llc | Glicoformas del factor viia. |
| JP6852397B2 (ja) | 2016-12-28 | 2021-03-31 | 株式会社島津製作所 | 分析用試料の調製方法および分析方法 |
| CN108114001B (zh) * | 2017-12-23 | 2023-05-30 | 中国科学院海洋研究所 | 一种诱导海产双壳贝类产卵的诱导剂及其应用方法 |
| WO2021248008A1 (en) | 2020-06-05 | 2021-12-09 | Innovation Pharmaceuticals Inc. | Arylamide compounds for treatment and prevention of viral infections |
| IL302388A (en) * | 2020-11-02 | 2023-06-01 | Attralus Inc | SAP FC fusion proteins and methods of use |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1562244A (en) * | 1976-11-11 | 1980-03-05 | Lock P M | Wound dressing materials |
| GB1594389A (en) * | 1977-06-03 | 1981-07-30 | Max Planck Gesellschaft | Dressing material for wounds |
| GB8516081D0 (en) | 1985-06-25 | 1985-07-31 | Ciba Geigy Ag | Assay & purification of amyloid components |
| US6071517A (en) * | 1986-07-07 | 2000-06-06 | Medarex, Inc. | Bispecific heteroantibodies with dual effector functions |
| EP0321703B1 (en) * | 1987-11-20 | 1993-04-28 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Absorbent for serum amyloid protein |
| US7070994B2 (en) * | 1988-03-21 | 2006-07-04 | Oxford Biomedica (Uk) Ltd. | Packaging cells |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5092876A (en) * | 1989-08-30 | 1992-03-03 | The United States Of America As Represented By The Department Of Health And Human Services | Cell attachment peptides derived from amyloid P component |
| EP0587777A4 (en) | 1991-05-31 | 1995-05-10 | New England Deaconess Hospital | CARCINOBRYONARY ANTIGEN BINDING PROTEINS AND METHODS OF ISOLATING AND USING THE SAME. |
| US5591709A (en) * | 1991-08-30 | 1997-01-07 | Life Medical Sciences, Inc. | Compositions and methods for treating wounds |
| CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US6054121A (en) * | 1993-02-26 | 2000-04-25 | The Picower Institute For Medical Research | Modulation of immune responses in blood-borne mesenchymal cells |
| US5804446A (en) * | 1993-02-26 | 1998-09-08 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| US5654186A (en) * | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
| AU7043694A (en) | 1993-05-27 | 1994-12-20 | Regents Of The University Of Michigan, The | Method of treatment and prevention of immune complex-induced lung injury |
| US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
| GB9317120D0 (en) * | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
| US5981470A (en) | 1994-06-07 | 1999-11-09 | The University Of Birmingham | Uterine fibroid treatment |
| US5989811A (en) * | 1994-09-29 | 1999-11-23 | Urocor, Inc. | Sextant core biopsy predictive mechanism for non-organ confined disease status |
| US6030815A (en) | 1995-04-11 | 2000-02-29 | Neose Technologies, Inc. | Enzymatic synthesis of oligosaccharides |
| US5922577A (en) | 1995-04-11 | 1999-07-13 | Cytel Corporation | Enzymatic synthesis of glycosidic linkages |
| US5876980A (en) | 1995-04-11 | 1999-03-02 | Cytel Corporation | Enzymatic synthesis of oligosaccharides |
| US5728554A (en) | 1995-04-11 | 1998-03-17 | Cytel Corporation | Enzymatic synthesis of glycosidic linkages |
| CA2204743C (en) * | 1995-09-13 | 2008-09-02 | Keiji Sakamoto | D-pantolactone hydrolase and gene encoding the same |
| US5750345A (en) | 1995-10-31 | 1998-05-12 | Evanston Hospital Corporation | Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders |
| AU712819B2 (en) | 1996-01-25 | 1999-11-18 | Profylakse Aps | Pharmaceutical composition comprising serum amyloid P component for proph ylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| AU8525098A (en) | 1997-07-24 | 1999-02-16 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| US6365570B1 (en) * | 1997-10-10 | 2002-04-02 | Universiteit Utrecht | Pharmaceutical and diagnostic use of Serum Amyloid P component |
| ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| IL137919A0 (en) * | 1998-02-17 | 2001-10-31 | Medarex Inc | Treating and diagnosing macrophage-mediated diseases using fc receptor ligands |
| DE99907899T1 (de) | 1998-03-11 | 2005-01-13 | Kabushiki Kaisha Soken | Hautnormalisierungsmittel |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| JPH11319542A (ja) | 1998-05-08 | 1999-11-24 | Tokuyama Corp | 超薄層の製造方法 |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6600019B2 (en) * | 2000-01-06 | 2003-07-29 | Curagen Corporation | Polypeptides and nucleic acids encoding same |
| EP1267795A1 (en) | 2000-03-30 | 2003-01-02 | Brennen Medical Inc. | Anti-microbial and immunostimulating composition |
| US20040068095A1 (en) * | 2001-03-14 | 2004-04-08 | Shimkets Richard A. | Novel human proteins, polynucleotides encoding them and methods of using the same |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| US6872541B2 (en) * | 2001-07-25 | 2005-03-29 | Coulter International Corp. | Method and compositions for analysis of pentraxin receptors as indicators of disease |
| US6537811B1 (en) * | 2001-08-01 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of SAP-1 expression |
| US20030199442A1 (en) | 2001-10-09 | 2003-10-23 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| JP2004049214A (ja) | 2001-11-29 | 2004-02-19 | Nippon Shokubai Co Ltd | 蛋白質またはペプチドの細胞内導入方法 |
| US7022476B2 (en) * | 2002-02-26 | 2006-04-04 | New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery | Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof |
| GB0211136D0 (en) | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
| US20050182042A1 (en) * | 2002-05-17 | 2005-08-18 | Feldman David L. | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
| JP4819364B2 (ja) * | 2002-12-23 | 2011-11-24 | ウイリアム、マーシュ、ライス、ユーニヴァーサティ | 線維細胞形成阻害の検出方法、ならびに線維細胞形成を増強する方法および化合物 |
| US7763256B2 (en) * | 2002-12-23 | 2010-07-27 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation |
| US8012472B2 (en) * | 2002-12-23 | 2011-09-06 | William Marsh Rice University | Compositions and methods for suppressing fibrocytes |
| JP2006526140A (ja) | 2002-12-24 | 2006-11-16 | バイオサイト インコーポレイテッド | 鑑別診断のためのマーカーおよびその使用方法 |
| US20070149450A1 (en) | 2003-02-27 | 2007-06-28 | Ranjit Bhardwaj | Method for reducing levels of c-reactive protein |
| MXPA06011796A (es) | 2004-04-16 | 2007-05-07 | Macrogenics Inc | Anticuerpos especificos de fc(riib y metodos para el uso de los mismos. |
| KR101297146B1 (ko) | 2004-05-10 | 2013-08-21 | 마크로제닉스, 인크. | 인간화 ＦｃγＲＩＩＢ 특이적 항체 및 그의 사용 방법 |
| WO2006002438A2 (en) | 2004-06-03 | 2006-01-05 | Medarex, Inc. | Human monoclonal antibodies to fc gamma receptor i (cd64) |
| WO2006002930A2 (en) | 2004-06-30 | 2006-01-12 | Friedrich-Alexander- Universitaet Erlangen- Nuernberg | FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS |
| ZA200701783B (en) | 2004-09-02 | 2009-10-28 | Genentech Inc | Anti-Fc-gamma RIIB receptor antibody and uses therefor |
| US7553653B2 (en) * | 2004-09-17 | 2009-06-30 | Biomarin Pharmaceutical Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| WO2006039418A2 (en) | 2004-09-30 | 2006-04-13 | Medarex, Inc. | Human monoclonal antibodies to fc gamma receptor ii (cd32) |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US20070099251A1 (en) | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20070243163A1 (en) | 2006-02-17 | 2007-10-18 | Chih-Ping Liu | Respiratory tract delivery of interferon-tau |
| US8247370B2 (en) * | 2006-12-04 | 2012-08-21 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
| US8497243B2 (en) * | 2007-07-06 | 2013-07-30 | Promedior, Inc. | Methods and compositions useful in the treatment of mucositis |
| ES2554167T3 (es) | 2007-07-06 | 2015-12-16 | Promedior Inc. | Métodos y composiciones útiles en el tratamiento de mucositis |
| US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| JP5797565B2 (ja) * | 2009-03-11 | 2015-10-21 | プロメディオール， インコーポレイテッド | 過敏性障害（ｈｙｐｅｒｓｅｎｓｉｔｉｖｅ ｄｉｓｏｒｄｅｒ）に対する処置および診断方法 |
| CA2755047C (en) * | 2009-03-11 | 2018-12-04 | Promedior, Inc. | Treatment methods for autoimmune disorders |
| US20100266643A1 (en) | 2009-04-01 | 2010-10-21 | Willett W Scott | Pulmonary and nasal delivery of serum amyloid p |
| UA110323C2 (en) | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| ES2552793T3 (es) * | 2009-06-17 | 2015-12-02 | Promedior Inc. | Variantes de SAP y su uso |
-
2010
- 2010-04-06 UA UAA201115614A patent/UA110323C2/ru unknown
- 2010-06-04 EA EA201171490A patent/EA030332B1/ru unknown
- 2010-06-04 MY MYPI2011005861A patent/MY158761A/en unknown
- 2010-06-04 PT PT15197076T patent/PT3042915T/pt unknown
- 2010-06-04 EP EP10784210.6A patent/EP2438083B1/en active Active
- 2010-06-04 US US12/794,132 patent/US9296800B2/en active Active
- 2010-06-04 MX MX2011012738A patent/MX2011012738A/es active IP Right Grant
- 2010-06-04 BR BR122020010980-7A patent/BR122020010980B1/pt active IP Right Grant
- 2010-06-04 JP JP2012514212A patent/JP5801293B2/ja active Active
- 2010-06-04 CA CA2764461A patent/CA2764461C/en active Active
- 2010-06-04 CN CN201080028923.8A patent/CN102574902B/zh active Active
- 2010-06-04 TR TR2018/15592T patent/TR201815592T4/tr unknown
- 2010-06-04 NZ NZ596849A patent/NZ596849A/xx unknown
- 2010-06-04 HU HUE10784210A patent/HUE026737T2/en unknown
- 2010-06-04 LT LTEP15197076.1T patent/LT3042915T/lt unknown
- 2010-06-04 PL PL10784210T patent/PL2438083T3/pl unknown
- 2010-06-04 WO PCT/US2010/037542 patent/WO2010141918A1/en active Application Filing
- 2010-06-04 BR BRPI1012924A patent/BRPI1012924B8/pt active IP Right Grant
- 2010-06-04 ES ES15197076.1T patent/ES2692815T3/es active Active
- 2010-06-04 AU AU2010256426A patent/AU2010256426B2/en active Active
- 2010-06-04 SI SI201031760T patent/SI3042915T1/sl unknown
- 2010-06-04 SI SI201031135T patent/SI2438083T1/sl unknown
- 2010-06-04 DK DK10784210.6T patent/DK2438083T3/da active
- 2010-06-04 PL PL15197076T patent/PL3042915T3/pl unknown
- 2010-06-04 DK DK15197076.1T patent/DK3042915T3/da active
- 2010-06-04 ES ES10784210.6T patent/ES2563748T3/es active Active
- 2010-06-04 EP EP15197076.1A patent/EP3042915B1/en active Active
-
2011
- 2011-11-29 CR CR20110640A patent/CR20110640A/es unknown
- 2011-12-01 IL IL216744A patent/IL216744A/en active IP Right Grant
- 2011-12-01 ZA ZA2011/08857A patent/ZA201108857B/en unknown
- 2011-12-21 CO CO11176414A patent/CO6480917A2/es active IP Right Grant
-
2012
- 2012-08-02 HK HK12107623.6A patent/HK1168603A1/zh unknown
-
2015
- 2015-03-27 JP JP2015067656A patent/JP2015120754A/ja active Pending
-
2016
- 2016-03-01 HR HRP20160221T patent/HRP20160221T1/hr unknown
-
2017
- 2017-02-10 JP JP2017023183A patent/JP2017082008A/ja active Pending
- 2017-04-20 US US15/492,085 patent/US20180044387A1/en not_active Abandoned
-
2018
- 2018-10-19 CY CY181101079T patent/CY1120817T1/el unknown
- 2018-10-31 HR HRP20181803TT patent/HRP20181803T1/hr unknown
-
2019
- 2019-12-31 US US16/731,320 patent/US20200369735A1/en not_active Abandoned
-
2020
- 2020-07-28 US US16/941,515 patent/US20210179679A1/en not_active Abandoned
-
2022
- 2022-03-15 US US17/695,071 patent/US20230058309A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230058309A1 (en) | Serum amyloid p derivatives and their preparation and use | |
| JP6124943B2 (ja) | Ｓａｐ変異体及びその使用 | |
| US20200362003A1 (en) | IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| ZA200607492B (en) | Y2/Y4 selective receptor agonists for therapeutic interventions | |
| EP3054959B1 (en) | Methods for treating fibrotic cancers | |
| JP2018535964A (ja) | 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置 | |
| Wang et al. | Glycosylation regulates N-terminal proteolysis and activity of the chemokine CCL14 | |
| KR20190003546A (ko) | 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도 | |
| US7084106B1 (en) | Application of a viral complement inhibitory protein in the treatment and diagnosis of Alzheimer's Disease | |
| SK287523B6 (sk) | Použitie CC chemokínového mutanta, farmaceutický prostriedok s obsahom chemokínového mutanta, skrátený a mutovaný humánny RANTES a spôsob jeho výroby | |
| WO2009108340A2 (en) | Leptin agonist and methods of use | |
| WO2000043027A1 (en) | Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease | |
| CN115996942A (zh) | 靶向巨噬细胞的肽及其缀合物、组合物和用途 |